Michael Ulz
Stock Analyst at Morgan Stanley
(4.45)
# 371
Out of 4,412 analysts
96
Total ratings
47.83%
Success rate
35.08%
Average return
Main Sectors:
Top Industries:
32 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Maintains: Overweight | $45 | $21.61 | +108.29% | 8 | Apr 22, 2024 | |
| ALPN Alpine Immune Sciences | Downgrades: Equal-Weight | $47 → $65 | $64.56 | +0.68% | 4 | Apr 11, 2024 | |
| KYTX Kyverna Therapeutics | Initiates: Overweight | $40 | $15.47 | +158.56% | 1 | Mar 4, 2024 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $3 → $7 | $3.80 | +84.21% | 7 | Feb 27, 2024 | |
| GUTS Fractyl Health | Initiates: Overweight | $18 | $6.70 | +168.66% | 1 | Feb 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $184 → $176 | $143.31 | +22.81% | 6 | Feb 13, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $34 → $36 | $22.12 | +62.75% | 3 | Feb 7, 2024 | |
| CABA Cabaletta Bio | Maintains: Overweight | $28 → $25 | $11.01 | +127.07% | 4 | Nov 29, 2023 | |
| MIRM Mirum Pharmaceuticals | Initiates: Overweight | $60 | $24.46 | +145.30% | 1 | Nov 13, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Equal-Weight | $45 → $48 | $41.59 | +15.41% | 4 | Nov 3, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $59 → $63 | $93.00 | -32.26% | 8 | Oct 27, 2023 | |
| AKRO Akero Therapeutics | Maintains: Overweight | $70 → $33 | $19.74 | +67.17% | 3 | Oct 11, 2023 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $27 | $8.07 | +234.57% | 2 | Aug 16, 2023 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $7 → $5 | $14.71 | -66.01% | 5 | Aug 14, 2023 | |
| THRD Third Harmonic Bio | Maintains: Equal-Weight | $5 → $7 | $10.83 | -35.36% | 3 | Aug 11, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Equal-Weight | $5 → $4 | $1.06 | +277.36% | 4 | Aug 7, 2023 | |
| ALVR AlloVir | Reiterates: Overweight | $20 | $0.80 | +2,409.10% | 2 | Aug 7, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $20 → $23 | $11.64 | +97.59% | 3 | May 23, 2023 | |
| SNTI Senti Biosciences | Maintains: Equal-Weight | $3 → $2 | $0.29 | +589.66% | 3 | Mar 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Overweight | $45 | $21.98 | +104.73% | 1 | Feb 1, 2023 | |
| XLO Xilio Therapeutics | Maintains: Overweight | $20 → $10 | $1.09 | +817.43% | 3 | Jan 27, 2023 | |
| ALLK Allakos | Maintains: Equal-Weight | $6 → $8 | $1.02 | +684.31% | 5 | Jan 27, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Equal-Weight | $3 | $2.39 | +25.52% | 1 | Jan 27, 2023 | |
| VIR Vir Biotechnology | Upgrades: Equal-Weight | $18 → $30 | $8.23 | +264.52% | 1 | Jan 27, 2023 | |
| IGMS IGM Biosciences | Maintains: Equal-Weight | $25 → $30 | $9.40 | +219.15% | 3 | Mar 30, 2022 | |
| AVRO AVROBIO | Maintains: Equal-Weight | $7 → $3 | $1.21 | +147.93% | 2 | Jan 5, 2022 | |
| ITOS iTeos Therapeutics | Initiates: Outperform | n/a | $10.80 | - | 1 | Oct 8, 2020 | |
| BCEL Atreca | Initiates: Outperform | n/a | $0.08 | - | 1 | Apr 16, 2020 | |
| MACK Merrimack Pharmaceuticals | Maintains: Neutral | n/a | $14.73 | - | 2 | Oct 22, 2018 | |
| MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $2.94 | - | 1 | May 8, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | n/a | $44.24 | - | 1 | Nov 3, 2017 | |
| FOLD Amicus Therapeutics | Maintains: Outperform | n/a | $10.28 | - | 2 | Jul 12, 2017 |
Silence Therapeutics
Apr 22, 2024
Maintains: Overweight
Price Target: $45
Current: $21.61
Upside: +108.29%
Alpine Immune Sciences
Apr 11, 2024
Downgrades: Equal-Weight
Price Target: $47 → $65
Current: $64.56
Upside: +0.68%
Kyverna Therapeutics
Mar 4, 2024
Initiates: Overweight
Price Target: $40
Current: $15.47
Upside: +158.56%
Fate Therapeutics
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $3.80
Upside: +84.21%
Fractyl Health
Feb 27, 2024
Initiates: Overweight
Price Target: $18
Current: $6.70
Upside: +168.66%
Alnylam Pharmaceuticals
Feb 13, 2024
Maintains: Equal-Weight
Price Target: $184 → $176
Current: $143.31
Upside: +22.81%
Arrowhead Pharmaceuticals
Feb 7, 2024
Maintains: Equal-Weight
Price Target: $34 → $36
Current: $22.12
Upside: +62.75%
Cabaletta Bio
Nov 29, 2023
Maintains: Overweight
Price Target: $28 → $25
Current: $11.01
Upside: +127.07%
Mirum Pharmaceuticals
Nov 13, 2023
Initiates: Overweight
Price Target: $60
Current: $24.46
Upside: +145.30%
Ionis Pharmaceuticals
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $41.59
Upside: +15.41%
Blueprint Medicines
Oct 27, 2023
Maintains: Equal-Weight
Price Target: $59 → $63
Current: $93.00
Upside: -32.26%
Akero Therapeutics
Oct 11, 2023
Maintains: Overweight
Price Target: $70 → $33
Current: $19.74
Upside: +67.17%
ORIC Pharmaceuticals
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $8.07
Upside: +234.57%
Y-mAbs Therapeutics
Aug 14, 2023
Maintains: Underweight
Price Target: $7 → $5
Current: $14.71
Upside: -66.01%
Third Harmonic Bio
Aug 11, 2023
Maintains: Equal-Weight
Price Target: $5 → $7
Current: $10.83
Upside: -35.36%
Karyopharm Therapeutics
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $1.06
Upside: +277.36%
AlloVir
Aug 7, 2023
Reiterates: Overweight
Price Target: $20
Current: $0.80
Upside: +2,409.10%
Iovance Biotherapeutics
May 23, 2023
Maintains: Outperform
Price Target: $20 → $23
Current: $11.64
Upside: +97.59%
Senti Biosciences
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.29
Upside: +589.66%
Rocket Pharmaceuticals
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $21.98
Upside: +104.73%
Xilio Therapeutics
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $1.09
Upside: +817.43%
Allakos
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $1.02
Upside: +684.31%
Taysha Gene Therapies
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $2.39
Upside: +25.52%
Vir Biotechnology
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $8.23
Upside: +264.52%
IGM Biosciences
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $9.40
Upside: +219.15%
AVROBIO
Jan 5, 2022
Maintains: Equal-Weight
Price Target: $7 → $3
Current: $1.21
Upside: +147.93%
iTeos Therapeutics
Oct 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $10.80
Upside: -
Atreca
Apr 16, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.08
Upside: -
Merrimack Pharmaceuticals
Oct 22, 2018
Maintains: Neutral
Price Target: n/a
Current: $14.73
Upside: -
Mersana Therapeutics
May 8, 2018
Initiates: Outperform
Price Target: n/a
Current: $2.94
Upside: -
Ultragenyx Pharmaceutical
Nov 3, 2017
Maintains: Outperform
Price Target: n/a
Current: $44.24
Upside: -
Amicus Therapeutics
Jul 12, 2017
Maintains: Outperform
Price Target: n/a
Current: $10.28
Upside: -